New molecular targets identified in some hard-to-treat melanomas

December 17, 2013

Two novel BRAF fusions were identified in melanomas previously considered to be negative for molecular targets, and melanomas with these fusions were found to be potentially sensitive to anticancer drugs called MEK inhibitors, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"About 35 percent of melanomas are, as of today, considered 'pan-negative,' which means they are devoid of any previously known driver mutations in the genes BRAF, NRAS, KIT, GNAQ, and GNA11," said Jeffrey A. Sosman, M.D., professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and a Stand Up To Cancer Melanoma Dream Team investigator. "Here at Vanderbilt, we have been interested in looking at patients whose tumors have none of these driver mutations, to see what their tumors do have that can be targeted therapeutically.

"We used the FoundationOne platform to perform a sophisticated analysis called targeted next-generation sequencing. Based on our findings, it appears that about 8 percent of pan-negative melanomas have BRAF fusions," said Sosman. "Our results are important because they obviously suggest that there probably are other, as yet unidentified, molecular changes that make these melanomas susceptible to drugs that are available right now."

In some cancers, two or more genes fuse erroneously to produce abnormal proteins, which can function as the "drivers" of those cancers.

In a pan-negative melanoma sample from one of their patients, Sosman; William Pao, M.D., Ph.D., a co-author on this study and a 2009 Stand Up To Cancer Innovative Research Grant recipient; and their colleagues identified a fusion between two genes, PAPSS1 and BRAF, which they called PAPSS1-BRAF. They then evaluated from an additional 51 patients, 24 of which were pan-negative. In one of these 24 pan-negative samples, they identified a second novel BRAF fusion, called TRIM24-BRAF.

The investigators conducted further studies in the laboratory and found that both BRAF fusions activated a pathway in the cells called the MAPK signaling pathway. They then treated these fusion-bearing cells either with the BRAF inhibitor vemurafenib or with trametinib, a drug that inhibits a protein in the MAPK signaling pathway called MEK. They found that signaling induced by the BRAF fusions was not responsive to vemurafenib but could be inhibited by trametinib, which led them to suggest that the novel fusions they identified could make melanoma cells harboring them sensitive to MEK inhibitors.

"Currently, there is immense value in identifying novel mutations in untreatable cancers because many of them are clinically relevant, which means they may be sensitive to drugs that are either being developed or are already FDA approved," said Sosman. "Our data support the idea that 'pan-negative' cancers are not truly pan-negative."

Explore further: Studies identify cell-signaling pathway alterations responsible for melanoma drug resistance

Related Stories

Studies identify cell-signaling pathway alterations responsible for melanoma drug resistance

November 22, 2013
Genomic profiling of treatment-resistant, BRAF-mutated melanomas revealed multiple gene alterations, mostly involving a cell-signaling pathway called the MAPK pathway, and more potent forms of existing drugs and drugs targeting ...

New biomarker may help guide treatment of melanoma patients

October 22, 2013
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC ...

Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy

July 16, 2012
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

Preclinical study indicates potential for novel inhibitor to overcome drug resistance induced by RAF, MEK inhibitors

April 8, 2013
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, ...

Enhanced treatment, surveillance needed for certain melanoma patients to prevent secondary cancers

August 14, 2013
Moffitt Cancer Center researchers suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF-inhibitor therapy ...

Stage III/IV melanoma patients at risk for new primaries

December 10, 2013
(HealthDay)—Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed ...

Recommended for you

Could a green sponge hold cancer-fighting secrets?

July 27, 2017
A small green sponge discovered in dark, icy waters of the Pacific off Alaska could be the first effective weapon against pancreatic cancer, researchers said on Wednesday.

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.